As the industry gears up for another big year, we take a deep dive into the TGA’s SAS-B data for 2023 to find out where things are heading. This service is available exclusively to Cannabiz Premium members. To upgrade to Premium, click here.
THC-only products accounted for nearly half the number of Special Access Scheme medicinal cannabis approvals in 2023 as figures show more women are turning to flower while approvals for anxiety continue to rise.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and
international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh.
Wondering what the SAS B data (47%) means for Victoria – ie. lots of GPs doing applications +/- Nurse Practitioner prescribing (who cannot become APs)